Seminar: Dr. Marta Sánchez-Carbayo

Bladder cancer progression: linking -omics, functional analyses and biomarkers

23 November 2012 00:00 hrs.
Bladder cancer progression: linking -omics, functional analyses and biomarkers

Dr. Marta Sánchez-Carbayo, Tumor Markers Group, Spanish National Cancer Research Center, Madrid, Spain



Prof. Bart Kiemeney, Scientific Director Nijmegen Centre for Evidence Based Practice

23-11-2012 00:00:00Europe/AmsterdamBladder cancer progression: linking -omics, functional analyses and biomarkers

Remarks / more information:

Sanchez-Carbayo, MartaOur research aims to characterize molecular mechanisms taking place in bladder cancer pathogenesis, and to translate the information of such analyses into biomarker tools that would improve the clinical management of bladder cancer patients. Our experimental strategy starts by integrating the information from the molecular characterization of bladder tumors using high-throughput approaches at the DNA, RNA and protein levels. Subsequent studies are designed: a) to understand how selected identified targets contribute to tumorigenesis and cancer progression; and b) to translate such information into multiplexed biomarkers using tissue (for disease stratification and outcome prediction) and body fluids (for early diagnosis and follow-up). More specifically, the major techniques we are currently investing on are epigenetic and proteomic approaches. Both are applied for identifying and validating individual and multiplexed biomarkers in clinical specimens, while proteomic approaches are additionally exploited for understanding molecular pathways by which genes of our interest (myopodin and KiSS-1, and others) are involved in bladder cancer. Our biomarker studies aim to address the four major clinical needs in bladder cancer: diagnosis, surveillance, progression into invasive and metastatic disease, and predict therapeutic response to the Bacille of Calmette-Guerin and cisplatin combinations.

<< back to all events